XBI – SPDR® S&P Biotech ETF
SPDR® S&P Biotech ETF (XBI) is a Health ETF, issued by State Street Investment Management, $10.4B in assets, 0.33% expense ratio.
Returns as of Oct 23, 2026: 1 week +3.6%, 1 year +41.1%.
Tracks S&P Biotechnology Select Industry Index, representing biotech segment of S&P Total Market Index. Uses sampling strategy, investing at least 80% in index securities.
Top holdings
- MRNA – Moderna Inc, 2.2%
- HALO – Halozyme Therapeutics Inc, 1.8%
- UTHR – United Therapeutics Corporation, 1.8%
- BIIB – Biogen Inc, 1.8%
- NTRA – Natera Inc, 1.7%
- EXEL – Exelixis Inc, 1.7%
- AMGN – Amgen Inc, 1.7%
- ABBV – AbbVie Inc, 1.7%
- IOVA – Iovance Biotherapeutics Inc, 1.6%
- SYRE – Spyre Therapeutics Inc., 1.6%
- VRTX – Vertex Pharmaceuticals Inc, 1.6%
- TWST – Twist Bioscience Corp, 1.6%
- GILD – Gilead Sciences Inc, 1.6%
- REGN – Regeneron Pharmaceuticals Inc, 1.5%
- PTGX – Protagonist Therapeutics Inc, 1.5%
- PTCT – PTC Therapeutics Inc, 1.5%
- CRSP – Crispr Therapeutics AG, 1.4%
- ALKS – Alkermes Plc, 1.4%
- TGTX – TG Therapeutics Inc, 1.4%
- ALNY – Alnylam Pharmaceuticals Inc, 1.4%
- KRYS – Krystal Biotech Inc, 1.4%
- ORKA – Oruka Therapeutics, Inc., 1.4%
- NBIX – Neurocrine Biosciences Inc, 1.3%
- ROIV – Roivant Sciences Ltd, 1.3%
- BBIO – BridgeBio Pharma Inc, 1.3%